Product information and disease descriptionPlace of product in therapyDisease description
Burden of Microcystic lymphatic malformations
8 evidence topics · 7 sources
Economic impact of diagnostic testing
No evidence found.
QTORIN rapamycin 3.9 percent gel
Microcystic lymphatic malformations
- Manufacturer
- Palvella Therapeutics
- Regulatory submission
- NDA submitted August 2026
- Last updated